Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 387

1.

Factors Associated With Follow-Up Care Among Women With Early-Stage Breast Cancer.

Quyyumi FF, Wright JD, Accordino MK, Buono D, Law CW, Hillyer GC, Neugut AI, Hershman DL.

J Oncol Pract. 2018 Nov 8:JOP1800229. doi: 10.1200/JOP.18.00229. [Epub ahead of print]

PMID:
30407882
2.

Obesity-associated breast inflammation among Hispanic/Latina breast cancer patients.

Greenlee H, Shi Z, Hibshoosh H, Giri DD, Ahmed A, Williams S, Falcone DJ, Winston LA, Zhou XK, Hudis CA, Hershman DL, Dannenberg AJ, Iyengar NM.

Cancer Prev Res (Phila). 2018 Nov 7. pii: canprevres.0207.2018. doi: 10.1158/1940-6207.CAPR-18-0207. [Epub ahead of print]

PMID:
30404870
3.

A randomized trial of interpersonal psychotherapy, problem solving therapy, and supportive therapy for major depressive disorder in women with breast cancer.

Blanco C, Markowitz JC, Hellerstein DJ, Nezu AM, Wall M, Olfson M, Chen Y, Levenson J, Onishi M, Varona C, Okuda M, Hershman DL.

Breast Cancer Res Treat. 2018 Oct 20. doi: 10.1007/s10549-018-4994-5. [Epub ahead of print]

PMID:
30343455
4.

Regional Market Competition and the Use of Immediate Breast Reconstruction After Mastectomy.

Wright JD, Chen L, Accordino M, Taback B, Ananth CV, Neugut AI, Hershman DL.

Ann Surg Oncol. 2018 Oct 16. doi: 10.1245/s10434-018-6825-7. [Epub ahead of print]

PMID:
30327971
5.

Effect of Minimum-Volume Standards on Patient Outcomes and Surgical Practice Patterns for Hysterectomy.

Ruiz MP, Chen L, Hou JY, Tergas AI, St Clair CM, Ananth CV, Neugut AI, Hershman DL, Wright JD.

Obstet Gynecol. 2018 Oct 5. doi: 10.1097/AOG.0000000000002912. [Epub ahead of print]

PMID:
30303921
6.

Phase II Feasibility Study of a Weight Loss Intervention in Female Breast and Colorectal Cancer Survivors (SWOG S1008).

Greenlee H, Lew DL, Hershman DL, Newman VA, Hansen L, Hartman SJ, Korner J, Shi Z, Sardo Molmenti CL, Sayegh A, Fehrenbacher L, Lo S, Klemp J, Rinn K, Robertson JM, Unger J, Gralow J, Albain K, Krouse R, Fabian C.

Obesity (Silver Spring). 2018 Oct;26(10):1539-1549. doi: 10.1002/oby.22269. Epub 2018 Sep 11.

PMID:
30272836
7.

National Cancer Institute Breast Cancer Steering Committee Working Group Report on Meaningful and Appropriate End Points for Clinical Trials in Metastatic Breast Cancer.

Seidman AD, Bordeleau L, Fehrenbacher L, Barlow WE, Perlmutter J, Rubinstein L, Wedam SB, Hershman DL, Hayes JF, Butler LP, Smith ML, Regan MM, Beaver JA, Amiri-Kordestani L, Rastogi P, Zujewski JA, Korde LA.

J Clin Oncol. 2018 Sep 13:JCO1800242. doi: 10.1200/JCO.18.00242. [Epub ahead of print]

PMID:
30212295
8.

Omega-3 fatty acid use for obese breast cancer patients with aromatase inhibitor-related arthralgia (SWOG S0927).

Shen S, Unger JM, Crew KD, Till C, Greenlee H, Gralow J, Dakhil SR, Minasian LM, Wade JL 3rd, Fisch MJ, Henry NL, Hershman DL.

Breast Cancer Res Treat. 2018 Aug 29. doi: 10.1007/s10549-018-4946-0. [Epub ahead of print]

PMID:
30159789
9.

Use and Outcomes of Minimally Invasive Hysterectomy for Women with Non-Endometrioid Endometrial Cancers.

Nieto VL, Huang Y, Hou JY, Tergas AI, St Clair CM, Ananth CV, Neugut AI, Hershman DL, Wright JD.

Am J Obstet Gynecol. 2018 Aug 4. pii: S0002-9378(18)30651-3. doi: 10.1016/j.ajog.2018.07.028. [Epub ahead of print]

PMID:
30086293
10.

Reply to T.P. Houston et al.

Hershman DL, Unger JM.

J Clin Oncol. 2018 Sep 20;36(27):2810-2811. doi: 10.1200/JCO.18.00285. Epub 2018 Jul 23. No abstract available.

PMID:
30036115
11.

Integrating value of research into NCI Clinical Trials Cooperative Group research review and prioritization: A pilot study.

Carlson JJ, Kim DD, Guzauskas GF, Bennette CS, Veenstra DL, Basu A, Hendrix N, Hershman DL, Baker L, Ramsey SD.

Cancer Med. 2018 Sep;7(9):4251-4260. doi: 10.1002/cam4.1657. Epub 2018 Jul 20.

12.

Effect of Acupuncture vs Sham Acupuncture or Waitlist Control on Joint Pain Related to Aromatase Inhibitors Among Women With Early-Stage Breast Cancer: A Randomized Clinical Trial.

Hershman DL, Unger JM, Greenlee H, Capodice JL, Lew DL, Darke AK, Kengla AT, Melnik MK, Jorgensen CW, Kreisle WH, Minasian LM, Fisch MJ, Henry NL, Crew KD.

JAMA. 2018 Jul 10;320(2):167-176. doi: 10.1001/jama.2018.8907.

PMID:
29998338
13.

The scientific impact and value of large, NCI-sponsored randomized phase III cancer chemoprevention trials.

Unger JM, Barlow WE, Tangen CM, Ramsey SD, Thompson IM Jr, Klein EA, LeBlanc M, Blanke CD, Goodman PJ, Minasian LM, Nghiem VT, Hershman DL.

Cancer Epidemiol. 2018 Aug;55:117-122. doi: 10.1016/j.canep.2018.06.005. Epub 2018 Jun 21.

PMID:
29936140
14.

Changes in Surgical Volume and Outcomes Over Time for Women Undergoing Hysterectomy for Endometrial Cancer.

Wright JD, Ruiz MP, Chen L, Gabor LR, Tergas AI, St Clair CM, Hou JY, Ananth CV, Neugut AI, Hershman DL.

Obstet Gynecol. 2018 Jul;132(1):59-69. doi: 10.1097/AOG.0000000000002691.

PMID:
29889759
15.

Integrative Therapies During and After Breast Cancer Treatment: ASCO Endorsement of the SIO Clinical Practice Guideline.

Lyman GH, Greenlee H, Bohlke K, Bao T, DeMichele AM, Deng GE, Fouladbakhsh JM, Gil B, Hershman DL, Mansfield S, Mussallem DM, Mustian KM, Price E, Rafte S, Cohen L.

J Clin Oncol. 2018 Sep 1;36(25):2647-2655. doi: 10.1200/JCO.2018.79.2721. Epub 2018 Jun 11.

PMID:
29889605
16.

Utilization of ovarian transposition for fertility preservation among young women with pelvic malignancies who undergo radiotherapy.

Selter J, Grossman Becht LC, Huang Y, Ananth CV, Neugut AI, Hershman DL, Wright JD.

Am J Obstet Gynecol. 2018 Oct;219(4):415-417. doi: 10.1016/j.ajog.2018.05.037. Epub 2018 Jun 6. No abstract available.

PMID:
29883577
17.

Assessment of Electronic Alert to Reduce Overuse of Granulocyte Colony-Stimulating Factor in Patients Hospitalized for Febrile Neutropenia.

Accordino MK, Wright JD, Vasan S, Buono DL, Hu JC, Neugut AI, Hershman DL.

JAMA Oncol. 2018 Jul 1;4(7):996-998. doi: 10.1001/jamaoncol.2018.0818. No abstract available.

PMID:
29799974
18.

Characteristics associated with prolonged length of stay after hysterectomy for benign gynecologic conditions.

Agrawal S, Chen L, Tergas AI, Hou JY, St Clair CM, Ananth CV, Neugut AI, Hershman DL, Wright JD.

Am J Obstet Gynecol. 2018 Jul;219(1):89.e1-89.e15. doi: 10.1016/j.ajog.2018.05.001. Epub 2018 May 8.

PMID:
29750957
19.

Trends in Use and Survival Associated With Fertility-Sparing Trachelectomy for Young Women With Early-Stage Cervical Cancer.

Cui RR, Chen L, Tergas AI, Hou JY, St Clair CM, Neugut AI, Ananth CV, Hershman DL, Wright JD.

Obstet Gynecol. 2018 Jun;131(6):1085-1094. doi: 10.1097/AOG.0000000000002613.

PMID:
29742670
20.

Outcomes of Hysterectomy Performed by Very Low-Volume Surgeons.

Ruiz MP, Chen L, Hou JY, Tergas AI, St Clair CM, Ananth CV, Neugut AI, Hershman DL, Wright JD.

Obstet Gynecol. 2018 Jun;131(6):981-990. doi: 10.1097/AOG.0000000000002597.

PMID:
29742669
21.

Pre-surgical trial of the AKT inhibitor MK-2206 in patients with operable invasive breast cancer: a New York Cancer Consortium trial.

Kalinsky K, Sparano JA, Zhong X, Andreopoulou E, Taback B, Wiechmann L, Feldman SM, Ananthakrishnan P, Ahmad A, Cremers S, Sireci AN, Cross JR, Marks DK, Mundi P, Connolly E, Crew KD, Maurer MA, Hibshoosh H, Lee S, Hershman DL.

Clin Transl Oncol. 2018 May 7. doi: 10.1007/s12094-018-1888-2. [Epub ahead of print]

PMID:
29736694
22.

A New Framework for Patient Engagement in Cancer Clinical Trials Cooperative Group Studies.

Deverka PA, Bangs R, Kreizenbeck K, Delaney DM, Hershman DL, Blanke CD, Ramsey SD.

J Natl Cancer Inst. 2018 Jun 1;110(6):553-559. doi: 10.1093/jnci/djy064.

PMID:
29684151
23.

Personal and clinical social support and adherence to adjuvant endocrine therapy among hormone receptor-positive breast cancer patients in an integrated health care system.

Kroenke CH, Hershman DL, Gomez SL, Adams SR, Eldridge EH, Kwan ML, Ergas IJ, Kubo A, Kushi LH.

Breast Cancer Res Treat. 2018 Aug;170(3):623-631. doi: 10.1007/s10549-018-4774-2. Epub 2018 Apr 18.

PMID:
29671113
24.

Association of Cardiovascular Risk Factors With Cardiac Events and Survival Outcomes Among Patients With Breast Cancer Enrolled in SWOG Clinical Trials.

Hershman DL, Till C, Shen S, Wright JD, Ramsey SD, Barlow WE, Unger JM.

J Clin Oncol. 2018 Sep 10;36(26):2710-2717. doi: 10.1200/JCO.2017.77.4414. Epub 2018 Mar 27.

PMID:
29584550
25.

Trends in Sentinel Lymph Node Mapping and Adjuvant Therapy in Endometrial Carcinoma.

Gómez-Hidalgo NR, Chen L, Hou JY, Tergas AI, St Clair CM, Ananth CV, Hershman DL, Wright JD.

Cancer Invest. 2018 Mar 16;36(3):190-198. doi: 10.1080/07357907.2018.1449212. Epub 2018 Mar 22.

PMID:
29565689
26.

Identifying modifiable and non-modifiable risk factors associated with prolonged length of stay after hysterectomy for uterine cancer.

Agrawal S, Chen L, Tergas AI, Hou JY, St Clair CM, Ananth CV, Hershman DL, Wright JD.

Gynecol Oncol. 2018 Jun;149(3):545-553. doi: 10.1016/j.ygyno.2018.03.048. Epub 2018 Mar 17.

PMID:
29559171
27.

Supplement Use and Chemotherapy-Induced Peripheral Neuropathy in a Cooperative Group Trial (S0221): The DELCaP Study.

Zirpoli GR, McCann SE, Sucheston-Campbell LE, Hershman DL, Ciupak G, Davis W, Unger JM, Moore HCF, Stewart JA, Isaacs C, Hobday TJ, Salim M, Hortobagyi GN, Gralow JR, Budd GT, Albain KS, Ambrosone CB.

J Natl Cancer Inst. 2017 Dec 1;109(12). doi: 10.1093/jnci/djx098.

28.

Using Medicare Claims to Examine Long-term Prostate Cancer Risk of Finasteride in the Prostate Cancer Prevention Trial.

Unger JM, Hershman DL, Till C, Tangen CM, Barlow WE, Ramsey SD, Goodman PJ, Thompson IM Jr.

J Natl Cancer Inst. 2018 Mar 9. doi: 10.1093/jnci/djy035. [Epub ahead of print]

PMID:
29534197
29.

Impact of hospital volume on racial disparities and outcomes for endometrial cancer.

Buskwofie A, Huang Y, Tergas AI, Hou JY, Ananth CV, Neugut AI, Hershman DL, Wright JD.

Gynecol Oncol. 2018 May;149(2):329-336. doi: 10.1016/j.ygyno.2018.02.019. Epub 2018 Mar 2.

PMID:
29506862
30.

Dynamic Diffuse Optical Tomography for Monitoring Neoadjuvant Chemotherapy in Patients with Breast Cancer.

Gunther JE, Lim EA, Kim HK, Flexman M, Altoé M, Campbell JA, Hibshoosh H, Crew KD, Kalinsky K, Hershman DL, Hielscher AH.

Radiology. 2018 Jun;287(3):778-786. doi: 10.1148/radiol.2018161041. Epub 2018 Feb 12.

PMID:
29431574
31.

Use and impact of herpes zoster prophylaxis in myeloma patients treated with proteasome inhibitors.

Leng S, Lentzsch S, Shen Y, Tsai WY, Wright JD, Hershman DL, Neugut AI.

Leuk Lymphoma. 2018 Feb 2:1-5. doi: 10.1080/10428194.2018.1429605. [Epub ahead of print] No abstract available.

PMID:
29390929
32.

Survival by Hispanic ethnicity among patients with cancer participating in SWOG clinical trials.

Chavez-MacGregor M, Unger JM, Moseley A, Ramsey SD, Hershman DL.

Cancer. 2018 Apr 15;124(8):1760-1769. doi: 10.1002/cncr.31241. Epub 2018 Jan 25.

PMID:
29370458
33.

Two-Year Trends of Taxane-Induced Neuropathy in Women Enrolled in a Randomized Trial of Acetyl-L-Carnitine (SWOG S0715).

Hershman DL, Unger JM, Crew KD, Till C, Greenlee H, Minasian LM, Moinpour CM, Lew DL, Fehrenbacher L, Wade JL 3rd, Wong SF, Fisch MJ, Lynn Henry N, Albain KS.

J Natl Cancer Inst. 2018 Jun 1;110(6):669-676. doi: 10.1093/jnci/djx259.

PMID:
29361042
34.

Racial disparities in young women with endometrial cancer.

Mukerji B, Baptiste C, Chen L, Tergas AI, Hou JY, Ananth CV, Neugut AI, Hershman DL, Wright JD.

Gynecol Oncol. 2018 Mar;148(3):527-534. doi: 10.1016/j.ygyno.2017.12.032. Epub 2018 Jan 5.

PMID:
29307452
35.

Understanding Breast Cancer Knowledge and Barriers to Treatment Adherence: A Qualitative Study Among Breast Cancer Survivors.

Freedman RA, Revette AC, Hershman DL, Silva K, Sporn NJ, Gagne JJ, Kouri EM, Keating NL.

Biores Open Access. 2017 Dec 1;6(1):159-168. doi: 10.1089/biores.2017.0028. eCollection 2017.

36.

Genome-wide meta-analyses identifies novel taxane-induced peripheral neuropathy-associated loci.

Sucheston-Campbell LE, Clay-Gilmour AI, Barlow WE, Budd GT, Stram DO, Haiman CA, Sheng X, Yan L, Zirpoli G, Yao S, Jiang C, Owzar K, Hershman D, Albain KS, Hayes DF, Moore HC, Hobday TJ, Stewart JA, Rizvi A, Isaacs C, Salim M, Gralow JR, Hortobagyi GN, Livingston RB, Kroetz DL, Ambrosone CB.

Pharmacogenet Genomics. 2018 Feb;28(2):49-55. doi: 10.1097/FPC.0000000000000318.

PMID:
29278617
37.

Association Between Hospital Financial Distress and Immediate Breast Reconstruction Surgery After Mastectomy Among Women With Ductal Carcinoma In Situ.

Richards CA, Rundle AG, Wright JD, Hershman DL.

JAMA Surg. 2018 Apr 1;153(4):344-351. doi: 10.1001/jamasurg.2017.5018.

PMID:
29214316
38.

Adherence to treatment recommendations and outcomes for women with ovarian cancer at first recurrence.

Champer M, Huang Y, Hou JY, Tergas AI, Burke WM, Hillyer GC, Ananth CV, Neugut AI, Hershman DL, Wright JD.

Gynecol Oncol. 2018 Jan;148(1):19-27. doi: 10.1016/j.ygyno.2017.11.008. Epub 2017 Nov 16.

PMID:
29153542
39.

The modified frailty index and 30-day adverse events in oncologic neurosurgery.

Youngerman BE, Neugut AI, Yang J, Hershman DL, Wright JD, Bruce JN.

J Neurooncol. 2018 Jan;136(1):197-206. doi: 10.1007/s11060-017-2644-0. Epub 2017 Nov 14.

PMID:
29139096
40.

Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor-Associated Arthralgias in Early-Stage Breast Cancer: SWOG S1202.

Henry NL, Unger JM, Schott AF, Fehrenbacher L, Flynn PJ, Prow DM, Sharer CW, Burton GV, Kuzma CS, Moseley A, Lew DL, Fisch MJ, Moinpour CM, Hershman DL, Wade JL 3rd.

J Clin Oncol. 2018 Feb 1;36(4):326-332. doi: 10.1200/JCO.2017.74.6651. Epub 2017 Nov 14.

41.

Cost of Care for the Initial Management of Ovarian Cancer.

Bercow AS, Chen L, Chatterjee S, Tergas AI, Hou JY, Burke WM, Ananth CV, Neugut AI, Hershman DL, Wright JD.

Obstet Gynecol. 2017 Dec;130(6):1269-1275. doi: 10.1097/AOG.0000000000002317.

PMID:
29112648
42.

Estimating global treatment toxicity burden from adverse-event data.

Lee SM, Hershman DL, Miao J, Zhong X, Unger JM, Cheung YKK.

Cancer. 2018 Feb 15;124(4):858-864. doi: 10.1002/cncr.31107. Epub 2017 Nov 7.

PMID:
29112232
43.

American Society of Clinical Oncology Summit on Addressing Obesity Through Multidisciplinary Provider Collaboration: Key Findings and Recommendations for Action.

Ligibel JA, Alfano CM, Hershman DL, Merrill JK, Basen-Engquist K, Bloomgarden ZT, Demark-Wahnefried W, Dixon S, Hassink SG, Jakicic JM, Morton JM, Okwuosa TM, Powell-Wiley TM, Rothberg AE, Stephens M, Streett SE, Wild RA, Westman EA, Williams RJ, Wollins DS, Hudis CA.

Obesity (Silver Spring). 2017 Nov;25 Suppl 2:S34-S39. doi: 10.1002/oby.21987.

44.

Failure to Rescue and Mortality Following Resection of Intracranial Neoplasms.

Malone H, Cloney M, Yang J, Hershman DL, Wright JD, Neugut AI, Bruce JN.

Neurosurgery. 2018 Aug 1;83(2):263-269. doi: 10.1093/neuros/nyx354.

PMID:
28973498
45.

National Trends in Extended Procedures for Ovarian Cancer Debulking Surgery.

Jones NL, Chen L, Chatterjee S, Tergas AI, Burke WM, Hou JY, Ananth CV, Neugut AI, Hershman DL, Wright JD.

Int J Gynecol Cancer. 2018 Jan;28(1):19-25. doi: 10.1097/IGC.0000000000001132.

PMID:
28953134
46.

Randomized phase III trial evaluating the role of weight loss in adjuvant treatment of overweight and obese women with early breast cancer (Alliance A011401): study design.

Ligibel JA, Barry WT, Alfano C, Hershman DL, Irwin M, Neuhouser M, Thomson CA, Delahanty L, Frank E, Spears P, Paskett ED, Hopkins J, Bernstein V, Stearns V, White J, Hahn O, Hudis C, Winer EP, Wadden TA, Goodwin PJ.

NPJ Breast Cancer. 2017 Sep 21;3:37. doi: 10.1038/s41523-017-0040-8. eCollection 2017. Review.

47.

All-cause mortality in young women with endometrial cancer receiving progesterone therapy.

Ruiz MP, Huang Y, Hou JY, Tergas AI, Burke WM, Ananth CV, Neugut AI, Hershman DL, Wright JD.

Am J Obstet Gynecol. 2017 Dec;217(6):669.e1-669.e13. doi: 10.1016/j.ajog.2017.08.007. Epub 2017 Aug 24.

PMID:
28844824
48.

Association of Hospital Volume and Quality of Care With Survival for Ovarian Cancer.

Wright JD, Chen L, Hou JY, Burke WM, Tergas AI, Ananth CV, Neugut AI, Hershman DL.

Obstet Gynecol. 2017 Sep;130(3):545-553. doi: 10.1097/AOG.0000000000002164.

49.

Association between survival time with metastatic breast cancer and aggressive end-of-life care.

Accordino MK, Wright JD, Vasan S, Neugut AI, Gross T, Hillyer GC, Hershman DL.

Breast Cancer Res Treat. 2017 Nov;166(2):549-558. doi: 10.1007/s10549-017-4420-4. Epub 2017 Jul 27.

50.

Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: a New York Cancer Consortium trial.

Adelson K, Ramaswamy B, Sparano JA, Christos PJ, Wright JJ, Raptis G, Han G, Villalona-Calero M, Ma CX, Hershman D, Baar J, Klein P, Cigler T, Budd GT, Novik Y, Tan AR, Tannenbaum S, Goel A, Levine E, Shapiro CL, Andreopoulou E, Naughton M, Kalinsky K, Waxman S, Germain D.

NPJ Breast Cancer. 2016 Dec 14;2:16037. doi: 10.1038/npjbcancer.2016.37. eCollection 2016.

Supplemental Content

Loading ...
Support Center